Nuclear and Cytoplasmic hTERT, Tumor-Infiltrating Lymphocytes, and Telomere Elongation Leukocytes Are Independent Factors in the Response to Neoadjuvant Treatment in HER2-Enriched Breast Cancer

HER2-enriched tumors are responsible for 20% of breast tumors and have high rates of immune infiltrates in the tumor stroma that respond favorably to neoadjuvant chemotherapy. In the context of tumors, telomeres control cell death and prevent tumor cells from replicating discontinuously, leading to their immortalization. This study aimed to evaluate the presence of tumor-infiltrating lymphocytes, hTERT expression, hTERT promoter mutation, and leukocyte telomere length in HER2-enriched breast tumors. A total of 103 cases were evaluated, 19 with pathologic complete response. The TILs percentage was above ≥10 in 44 cases (43%) and significantly present in patients ≥50 years of age. hTERT staining positivity was mostly nuclear, significantly present in the non-pCR group, and associated with a lower survival rate. Leukocyte telomeres were elongated for HER2-enriched tumors, and in multivariate analysis, shortening was associated with an increased risk of death. Overall, our results show that the nuclear and cytoplasmic presence of hTERT may indicate a worse prognosis and that leukocyte telomere elongation is a protective factor.

[1]  H. Takei,et al.  Subcellular localization of hTERT in breast cancer: Insights into its tumorigenesis and drug resistance mechanisms in HER2-immunopositive breast cancer. , 2022, Human pathology.

[2]  K. Hirakawa,et al.  Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age , 2022, World Journal of Surgical Oncology.

[3]  G. Gomatou,et al.  Differential immunohistochemical expression of hTERT in lung cancer patients with and without idiopathic pulmonary fibrosis. , 2022, Pulmonology.

[4]  W. Schiemann,et al.  Telomerase in Cancer: Function, Regulation, and Clinical Translation , 2022, Cancers.

[5]  Z. Varga,et al.  Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy , 2022, Scientific reports.

[6]  O. Belkacem,et al.  Prognostic value of tumor-infiltrating lymphocytes (TILS) and their association with clinicopathological features in breast cancer: A retrospective study involving 53 cases , 2021, Revista de Senología y Patología Mamaria.

[7]  S. Chandarlapaty,et al.  TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer , 2021, NPJ breast cancer.

[8]  M. Spitzer,et al.  Systemic immunity in cancer , 2021, Nature Reviews Cancer.

[9]  Jian-Min Yuan,et al.  Leukocyte telomere length, cancer incidence and all‐cause mortality among Chinese adults: Singapore Chinese Health Study , 2021, International journal of cancer.

[10]  T. Aoki,et al.  Significance of cytoplasmic expression of telomerase reverse transcriptase in patients with hepatocellular carcinoma undergoing liver resection , 2021, Molecular and clinical oncology.

[11]  N. T. Trung,et al.  Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma , 2020, Scientific Reports.

[12]  R. Ma,et al.  An Optimised Step-by-Step Protocol for Measuring Relative Telomere Length , 2020, Methods and protocols.

[13]  A. Yashin,et al.  Association of Leukocyte Telomere Length With Mortality Among Adult Participants in 3 Longitudinal Studies , 2020, JAMA network open.

[14]  A. Vincent-Salomon,et al.  Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy , 2019, Clinical Cancer Research.

[15]  G. Tang,et al.  Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination , 2019, Breast Cancer Research and Treatment.

[16]  M. Fournier,et al.  Mutation profiling in the PIK3CA, TP53, and CDKN2A genes in circulating free DNA and impalpable breast lesions. , 2019, Annals of diagnostic pathology.

[17]  S. Mathoulin-Pélissier,et al.  Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. , 2018, European journal of cancer.

[18]  Mike Clarke,et al.  Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials , 2018, The Lancet. Oncology.

[19]  P. Fasching,et al.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.

[20]  Masayuki Yoshida,et al.  TERT promoter hotspot mutations in breast cancer , 2017, Breast Cancer.

[21]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[22]  M. Blasco,et al.  Critically short telomeres and toxicity of chemotherapy in early breast cancer , 2017, Oncotarget.

[23]  E. Maunsell,et al.  Telomere Length and Breast Cancer Prognosis: A Systematic Review , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[24]  Y. Bignon,et al.  ERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosis , 2016, The journal of pathology. Clinical research.

[25]  I. Desideri,et al.  Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. , 2016, Cancer treatment reviews.

[26]  P. Gariglio,et al.  Shorter telomeres and high telomerase activity correlate with a highly aggressive phenotype in breast cancer cell lines , 2016, Tumor Biology.

[27]  M. Ladanyi,et al.  Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression , 2016, The Journal of pathology.

[28]  Carsten Denkert,et al.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  S Michiels,et al.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Neugut,et al.  Genetic polymorphisms in telomere pathway genes, telomere length, and breast cancer survival , 2012, Breast Cancer Research and Treatment.

[33]  Sunil R. Lakhani,et al.  WHO classification of tumours of the breast , 2012 .

[34]  Laura J. Esserman,et al.  Leukocyte composition of human breast cancer , 2011, Proceedings of the National Academy of Sciences.

[35]  P. Argani,et al.  Shorter telomeres in luminal B, HER-2 and triple-negative breast cancer subtypes , 2011, Modern Pathology.

[36]  J. Sakoff,et al.  Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the beta deletion variant. , 2008, Neoplasia.

[37]  S. Rosenberg,et al.  Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy1 , 2005, The Journal of Immunology.

[38]  R. Cawthon.  Telomere measurement by quantitative PCR. , 2002, Nucleic acids research.

[39]  W. Symmans,et al.  Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  G. Hagen,et al.  Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). , 1999, Gene.

[41]  B. Levine,et al.  Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Yutsudo,et al.  Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. , 1999, Cancer research.

[43]  Y. Cong,et al.  The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. , 1999, Human molecular genetics.

[44]  L. Giudice,et al.  Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. , 1998, Cancer research.

[45]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[46]  E. Blackburn,et al.  Structure and function of telomeres , 1991, Nature.